

Asian Oncology Research Journal

1(1): 15-19, 2018; Article no.AORJ.39480

Infantile Haemangioma in a 'Beard' Distribution: A Case Report

Iragbogie Al-Mustapha Imoudu^{1*}, Maimuna Orahachi Yusuf¹ and Hayatu Ahmad¹

¹Department of Paediatrics, Federal Medical Centre, PMB 005, Azare, 751101, Bauchi State, Nigeria.

Authors' contributions

This work was carried out in collaboration between all authors. Author IAMI wrote the draft of the manuscript. Author MOY wrote the case summary. Author HA conceptualised the report. All the authors read and approved the final draft of the manuscript.

Article Information

DOI: 10.9734/AORJ/2018/39480 <u>Editor(s)</u>: (1) Shafiahammedkhan Mustaqahamed, Department of Zoology, Human Genetics Laboratory, School of Life Sciences, Bharathiar University, Tamil Nadu, India & Managing Director of LifeDNA Diagnostic laboratory, Coimbatore. (2) Bing Yan, Department of Oncology, Hainan Branch of PLA General Hospital, Haitang District of Sanya City, Hainan Province, China. <u>Reviewers:</u> (1) Michael J. Nathenson, Dana-Farber Cancer Institute, USA. (2) Asaad Ahmed Ghanem, Mansoura University, Egypt. (3) Gabriella Marfe, University of Campania L. Vanvitelli Naples, Italy. Complete Peer review History: <u>http://www.sciencedomain.org/review-history/23536</u>

> Received 17th December 2017 Accepted 28th February 2018 Published 8th March 2018

Case Study

ABSTRACT

Aim: To highlight infantile haemangioma as a possible cause of upper airway obstruction in young infants presenting with stridor particularly when there are associated cutaneous lesions.

Presentation of Case: We report a 10 week-old baby girl admitted into the emergency paediatric unit of the Federal Medical Centre Azare, Nigeria with a 3-week history of a skin lesion initially noticed as a flat discoloured area over the sternal region. It progressively spread to involve the anterior aspect of the neck and chin and became associated with progressive difficulty with breathing. Examination findings revealed a restless, acutely ill child with inspiratory stridor. She had purplish plaques in the areas mentioned above as well as the lower lip and ventral aspect of the tongue. She improved remarkably following intranasal oxygen, intravenous dexamethasone and oral propranolol administration and was discharged after 4 days of admission on oral prednisolone and propranolol.

Discussion: Infantile haemangiomas are benign vascular neoplasms that have a characteristic clinical course marked by early proliferation and followed by spontaneous involution. Infrequently,

^{*}Corresponding author: E-mail: tomhe164@yahoo.com;

infantile haemangiomas may impinge on vital structures provoking certain related symptoms. Airway obstruction is an uncommon complication and may be particularly challenging for young infants who are obligate nose breathers. Subglottic haemangiomas are also uncommon compared to the cutaneous forms and may be life threatening with attendant airway obstruction. This was the foremost concern in our patient. Nevertheless, she responded to dexamethasone and propranolol. **Conclusion:** It is essential to recognize the association of infantile haemangiomas presenting in a beard distribution with airway obstruction and promptly institute management of respiratory complications.

Keywords: Infantile haemangioma; benign neoplasm; beard distribution; respiratory distress; Stridor; Azare.

1. INTRODUCTION

Infantile haemangiomas are the most frequently encountered benian vascular tumours of infancy and childhood. They are bright red, protuberant (may be macular or papular at onset), compressible, sharply demarcated lesions that may be found in any part of the body [1-4]. These tumours affect nearly one in ten infants with a higher incidence seen in preterm neonates and those who were exposed to chorionic villus sampling [3,4]. Haemangiomas are commoner in girls than boys with incidence ratios ranging from 3:1 - 4:1 respectively being variously quoted exact aetiology of [1,5]. The infantile haemangiomas is not known. However, it has been postulated that an association between immature endothelial cells and pericytes as well as angiogenic peptides, such as beta-fibroblast growth factor, vascular endothelial growth factor (VEGF), and proliferating cell nuclear antigen, give rise to the development of hemangiomas [6,7].

Most infantile haemangiomas undergo a phase of rapid expansion, followed by a stationary period and finally spontaneous involution. Even though most haemangiomas are not challenging requiring no treatment, about 10% may cause significant morbidity mainly through airway obstruction, ocular compression, functional impairment and ulceration [1,8]. Complications include ulceration, secondary infections and rarely haemorrhage. In the majority of cases haemangiomas are diagnosed based on history and examination findings. If diagnosis remains in doubt, colour doppler ultrasonography and/or MRI may prove helpful [1].

Treatment modalities currently in use for problematic haemangiomas are, drug therapy, laser therapy and surgery. Effective medications include, propranolol, timolol, corticosteroids, alpha-interferon, cyclophosphamide, vincristine, pinyangmycin, and imiquimoid [1].

Hemangiomas in a 'beard' distribution are uncommon and may present with involvement of the upper airways or the subglottic areas and associated respiratory complications [9]. We present this exceptional case underscoring the need for a high index of suspicion and anticipatory management of life threatening respiratory complications in children with infantile cutaneous haemangiomas in a 'beard' distribution.

2. PRESENTATION OF CASE

A 10 week-old baby girl presented to the Emergency Paediatric Unit (EPU) of the Federal Medical Centre Azare, Nigeria on account of a 3week history of raised multiple reddish rashes over the upper aspect of the chest. These progressively spread upwards to involve the anterior neck, lower jaw and lower lip. The lesions also spread laterally to involve the infraauricular region bilaterally. They were soft, non-discharging and subsequently painful, coalesced to form a huge mass. There were no swellings in any other part of the body and there was no bleeding either from the lesion or any other part of the body. At the time the lesion was noticed to have spread to the neck, she developed progressive difficulty with breathing, as well as noisy and fast breathing. There was no associated change in voice or drooling of saliva. She also developed an insidious onset cough, becoming progressively restless and refusing breast milk. This was the first episode of such symptoms in the child's life, there was no family history of a similar illness and she was delivered at term at a primary health facility following an unsupervised pregnancy.

On examination, she was acutely ill, in respiratory distress, and with inspiratory stridor.

She was febrile with an axillary temperature of 38°C. There were multiple plaques of various sizes on the supra-sternal region, anterior aspect of the neck, lower jaw, lower lip, buccal mucosa and the ventral surface of the tongue. These lesions were soft, non-tender, the largest measuring 8×3 cm in its widest diameter on the anterior chest wall. She had no dysmorphic features and anthropometric measurements were normal. The respiratory rate was 48 cpm, she was dyspnoeic, had vesicular breath sounds with widespread coarse crepitations bilaterally. A diagnosis of infantile haemangioma in a beard distribution with upper airway involvement and bronchopneumonia was made.

She was placed on intranasal oxygen via nasal prongs, intravenous ampiclox at 200 mg/kg/day in 6 hourly divided doses, gentamycin at 2.5 mg/kg 8 hourly and dexamethasone at 0.15 mg/kg/dose 6 hourly as well as oral propranolol 2 mg/kg/day bid. Her full blood count and differential count results as well as serum urea and electrolytes were normal. However, chest radiograph showed features consistent with bronchopneumonia.

Response to management was remarkable as she was able to breathe without distress, showed a gradual regression in the size of the lesions, became afebrile and was able to feed within 48 hours of commencement of treatment. Following complete recovery, she was discharged home on oral propranolol at 2 mg/kg/day, prednisolone at 2 mg/kg/day and oral ampiclox at 200 mg/kg/day after 4 days of admission to be followed up in the outpatient clinic. However, nine days after discharge, she re-presented to the EPU with the same symptoms. Her caregiver admitted to stopping the administration of prescribed medications 5 days earlier. She had the same treatment as in the previous admission with remarkable improvement noticed after a 24-hour period. Prior to discharge 2 days later, the caregiver was re-counselled on the disease including compliance to follow up and medications. Nonetheless, she was lost to follow up (she did not have any clinic visit).

3. DISCUSSION

Haemangiomas typically show rapid proliferation in infancy which may manifest with potentially life threatening complications as demonstrated by our patient [10,11]. Subglottic haemangiomas are uncommon compared to the cutaneous forms and may be life threatening in the proliferative phase with attendant airway obstruction [11]. This was the foremost concern in our patient. Yet, due to limited facilities in our centre we were unable to carry out some investigations eg. direct endobronchoscopy and MRI or magnetic resonance angiography (MRA) of the head and neck as well as immunohistochemistry for confirmation of diagnosis. These would have also aided in the determination of the extent of involvement of the airway and confirmation of subglottic affectation.

The index patient also presented with clinical and radiological features of bronchopneumonia, which is not a common finding in 'beard' presentation of infantile haemangiomas. However, infections have been known to complicate infantile haemangiomas particularly when they are ulcerated [1,4].

The effectiveness of corticosteroids and propranolol in infantile haemangiomas (as shown in our patient) is well documented [1,9,10]. Propranolol, a non-selective beta blocker is thought to act by vasoconstriction, decreasing growth factors and perhaps preventing the haemangioma stem cells from differentiating into endothelial cells or pericytes leading to involution. Steroids have a direct inhibitory effect angiogenesis and cause enhanced on expression of genes coding for markers of apoptosis [8,12-15]. These medications may have facilitated the regression of the tumours in this case resulting in marked improvement of symptoms. However, a lack of compliance to medications led to a resurgence of symptoms necessitating readmission. This has been well documented by some studies [16,17].

Steroids are mostly useful in the early proliferative phase of infantile haemangioma and are continued until tumour growth has stopped or a complete reduction in size is demonstrable. They are then gradually tapered [18]. Oral propranolol on the other hand is known to have early, intermediate and long-term effects [16]. The initial effect which is due to $\beta 2$ adrenergic inhibition (vasoconstriction) is usually obvious within 1-3 days of commencing therapy as demonstrated in this case [16]. The length of propranolol therapy is determined by the extent of involvement, the treatment indications and the morphology of the tumour. Some authors have suggested 6 months of treatment with adjustments for certain morphological subtypes. For instance, treatment may be continued for up to 12 months in cases of deep and mixed infantile haemangiomas [19]. We were unable to track the ultimate response and outcome in this case as a result of poor compliance to the management plan. There is the need to stress the importance of continued, uninterrupted medical therapy and follow up for such patients as they are at risk of tumour resurgence and life threatening airway compromise.

4. CONCLUSION

Airway obstruction is an uncommon complication of haemangiomas and may be more challenging for young infants who are obligate nose breathers We recommend that infantile haemangiomas of the upper airway be considered in young infants with respiratory distress and stridor especially when they present lesions. with cutaneous Anticipatory management of these respiratory complications may improve survival in resource-poor settings like ours.

CONSENT

As per international standard or university standard written patient consent has been collected and preserved by the authors.

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the authors.

ACKNOWLEDGEMENT

The authors thank all those involved in the management of this patient.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- 1. Zheng JW, Zhang L, Zhou Q, Mai HM, Wang YA, Fan XD, et al. A practical guide to treatment of infantile hemangiomas of the head and neck. Int J Clin Exp Med. 2013;6(10):851-60.
- 2. McGae P, Miller S, Black C, Hoey S. Propranolol for infantile haemangioma: A review of current dosing regime in a

regional paediatric hospital. Ulster Med J. 2013;82:16-20.

- 3. Zimmerman AP, Wiegand S, Werner JA, Eivazi B. Propranolol therapy for infantile haemangioma: Review of the literature. Int J Ped Otorhinolaryngol. 2010;74:338-42.
- 4. Leaute-Labreze Č, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390: 85-94.
- Scharwtz RA, Sidor MI, Musumeci ML, Lin RL, Micali G. Infantile haemangiomas: A challenge in paediatric dermatology. J Eur Acad Dermatol Venereol. 2010;24:631-8.
- Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93(93):2357-64.
- Ritter MR, Reinisch J, Friedlander SF, Friedlander M. Myeloid cells in infantile hemangioma. Am J Pathol. 2006;168(2): 621-8.
- Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: Insights into molecular mechanisms of action. Br J Dermatol. 2010;163:269-75.
- 9. Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a 'beard' distribution. J Pediatr. 1997;131:645-8.
- Ferreira RC, Wolff FR, Morschbacher R. Oral propranolol as a new treatment for facial infantile hemangiomas: Case report. Arq Bras Oftalmol. 2011;74(3):207-8.
- 11. Mendriatta V, Jabeen M. Infantile haemangioma: An update. Indian J Dermatol Venereol Leprol. 2010;76:469-75.
- Frieden IJ, Drolet BA. Propranolol for infantile hemangiomas: Promise, peril, pathogenesis. Pediatr Dermatol. 2009; 26(5):642-4.
- Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangioma- derived stem cells. N Engl J Med. 2010;362(11):1005-13.
- Vivas-Colmenares GV, Bernabeu-Wittel J, Alonso-Arroyo V, Matute de Cardenas JA, Fernandez-Pineda I. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase: A multicentre retrospective study. Pediatr Dermatol. 2015;32(3):348-52.

- Greenberger S, Bischoff J. Infantile hemangioma- mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med. 2011;1(1):a006460. Available:http:doi:10.1101/cshperspect.a00 6460 (Accessed 31 January 2018)
- 16. Sethuraman G, Yenamandra VK, Gupta V. Management of infantile hemangiomas: Current trends. J Cutan Aesthet Surg. 2014;7(2):75-85.
- 17. Price CJ, Lattouf C, Baum B, McLeod M, Schachner LA, Duarte AM, et al.

Propranolol vs corticosteroids for infantile hemangiomas: A multicenter retrospective analysis. Arch Dermatol. 2011;147:1371-6.

- Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: An evidence-based evaluation. Arch Dermatol. 2001;137:1208-13.
- Hogeling M, Adam S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128:259-66.

© 2018 Imoudu et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: http://www.sciencedomain.org/review-history/23536